Compounds acting as melanocortin receptor ligands

Details Compounds acting as melanocortin receptor ligands Compounds acting as melanocortin receptor ligands

2006-12-26

2006-12-26

McKane, Joseph K. (Department: 1626)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S415000, C514S427000, C514S634000, C548S361100, C548S483000, C548S517000, C548S518000, C548S561000, C564S230000, C564S237000

Reexamination Certificate

active

07153881

ABSTRACT:
The present invention provides novel compounds and use of compounds of general formula (I) as ligands to the melanocortin receptors and/or for treatment of disorders in the melanocortin system: Wherein X and Y are independently chosen from O, N, S and (CH2)n, where n is 0, 1, 2, 3, 4, or 5, or a combination of these and may contain carbon-carbon multiple bonds and branched chains as well as alicyclic and heterocyclic groups; Q is H or OH; R1and R2can be either the same or different and are chosen from hydrogen or the residue of an aromatic group as listed in Scheme 1 and the pharmacologically active salts thereof

REFERENCES:
patent: 3592935 (1971-07-01), Houlihan et al.
patent: 3896232 (1975-07-01), Houlihan et al.
patent: 3975533 (1976-08-01), Kodama et al.
patent: 3982020 (1976-09-01), Houlihan et al.
patent: 4006249 (1977-02-01), Porter et al.
patent: 4006250 (1977-02-01), Childress
patent: 5599984 (1997-02-01), Bianchi et al.
patent: 5750573 (1998-05-01), Bianchi et al.
patent: 5958933 (1999-09-01), Naftchi
patent: 6413962 (2002-07-01), Naftchi
patent: 6534546 (2003-03-01), Honda et al.
patent: 2004/0019094 (2004-01-01), Lundstedt et al.
patent: 20 20 230 (1970-12-01), None
patent: 34 28 342 (1986-02-01), None
patent: 0 505 322 (1992-09-01), None
patent: 1 368 644 (1971-12-01), None
patent: 1 521 594 (1976-09-01), None
patent: 055062017 (1980-10-01), None
patent: WO 93 03714 (1993-04-01), None
patent: 98/23267 (1998-04-01), None
patent: WO 99 64002 (1999-12-01), None
patent: WO 00 35952 (2000-06-01), None
patent: WO 01 25192 (2001-12-01), None
Xiang et al., 2000, CAS:132:166017.
William O. Foye et al., “Synthesis and Biological Activity of Guanythydrazones of 2- and 4-Pyridine and 4-Quinoline Carboxaldehydes”, Journal of Pharmaceutical Sciences, vol. 79, No. 6, Jun. 1990, pp. 527-530, XP002180467, American Pharmaceutical Association, Washington, US.
Rao, Y. Ramachandra, “Isomeric changes involving amidino and thioamidino systems. I. Conversion of 5-amino-2-arylamino-1,3,4-thiadiazoles into 5-amino-4-aryl-3-mercapto-1,2,4-triazoles”, Indian J. Chem. (1968), 6(6), 287-93.
Chang, J. et al., “The Antiinflammatory Action of Guanabenz is Mediated Through 5-Lipoxygenase and Cyclooxygenase Inhibition”, European Journal of Pharmacology, Amersterdam, NL., vol. 142, No. 2, 1987, pp. 197-205, XP000974753.
Dimmock J. R. et al., “Evaluation of the Thiosemicarbazones of Some Aryl Alkyl Ketones and Related Compounds for Anticonvulsant Activities”, European Journal of Medicinal Chemistry, Editions Scientifique Elsevier, Paris, FR, vol. 26, No. 5, 1991, pp. 529-534, XP002014742.
Southan Garry J. et al., “Hydroxyguanidines Inhibit Peroxynitrite-induced Oxidation”, Free Radical Biology & Medicine, vol. 25, No. 8, Nov. 15, 1998, pp. 914-925, XP002209697.
Kazic, T. et al., “Central Presynaptic alpha2 agonists guanabenz and clonidine act as alpha1 adrenoceptor antagonists in the isolated vas deferens of the guinea pig”, Iugosl, Phisiol. Pharmacol. Acta (1994), 30(1), 25-34, XP001098531.
Osawa Y et al., “Inactivation of penile nitric oxide synthase by Guanabenz, an antihypertensive agent: Potential implications in drug induced impotence”, FASEB Journal, vol. 9, No. 6, 1995, p. A1495, XP001095624.
Nakatsuka Mikiya et al., “Metabolism-based inactivation of penile nitric oxide synthase activity by Guanabenz”, Drug Metabolism and Disposition, vol. 25, No. 5, May 1998, pp. 497-501, XP001095628.
Benelli A et al., “Male sexual behavior: further studies on the role of the alpha 2-adrenoceptors”, Pharmacological Research: The Official Journal of the Italian Pharmacological Society, England, Jul.-Aug. 1993, vol. 28, No. 1, Jul. 1993, pp. 35-45, XP001095156.

Affiliated with

Also associated with

Rating

Compounds acting as melanocortin receptor ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Compounds acting as melanocortin receptor ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compounds acting as melanocortin receptor ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3668900